Psyched Wellness Has Commenced Research on Muscimol for Various Ailments

Toronto, Ontario--(Newsfile Corp.-December 28, 2020)-Psyched Wellness Ltd. (CSE: PSYC)(OTCQB: DCNPF) (FSE: 5U9) (formerly Duncan Park Holdings Corporation) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has commenced research on Muscimol for various ailments, with a focus on mental health issues.

The research is led by Psyched Wellness's board member, Prof. David Nutt. Prof. Nutt is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways.

The purpose of the research is to gather all the scientific papers surrounding Muscimol and its various ailments, in order to support using Muscimol for mental health issues.

"It is truly inspiring to work close with Prof. Nutt, and I am curious to read this substantial research, "said David Shisel, COO of the Company. "This research is the first step towards the pharmaceutical path, and will give our fast-growing company a road map to begin the first clinical trials on our extraction."